Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …

Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31)
receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai …

Considering the role of epidermal keratinocytes, they occupy more than 90% of the
epidermis, form a physical barrier, and also function as innate immune barrier. For example …

Atopic dermatitis, known also as atopic eczema, represents a commonly diagnosed, chronic
or recurrent/relapsing inflammatory disorder. From a clinical point of view, it is characterized …

The impact of new and emerging therapies on the microenvironment of primary cutaneous
lymphomas (PCLs) has been recently raised in the literature. Concomitantly, novel …

Background In recent years, biologics targeting key cytokines and Janus kinase (JAK)
inhibitors have demonstrated favorable efficacy and safety outcomes for atopic dermatitis …

Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts
quality of life. The pathogenesis of AD is a complex combination of skin barrier dysfunction …

Atopic dermatitis (AD) is one of the most common skin diseases, the prevalence of which is
especially high among children. Although our understanding about its pathogenesis has …

Atopic dermatitis (AD) is the most common inflammatory skin disease seen in children. It is a
heterogeneous disorder, with a variety of associated manifestations and symptoms. Cases …

The overactivity of keratinocyte cytoplasmic signaling contributes to several cutaneous
inflammatory and immune pathologies. An important emerging complement to proteins …